COMMUNIQUÉS West-GlobeNewswire

Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V
11/08/2026
Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence” Lower schedule expected to enhance patient access in the US Allschwil [...]
Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed
11/08/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed [...]
Exor and Philips Extend Long-term Relationship Agreement
11/08/2026
August 11, 2026 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. today announced that they have agreed to update their long-term relationship [...]
Solésence Reschedules Second Quarter 2026 Conference Call to August 19
11/08/2026
ROMEOVILLE, Ill., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company has [...]
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
11/08/2026
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
NORTH Performance Launches Globally with Pre-Sales Site and Founding Athlete Co-Owner Roster
11/08/2026
Next-generation all-in-one performance supplement brand, built on a radical athlete co-ownership model, opens pre-sales ahead of September 2026 product launch DOVER, Del., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NORTH [...]
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
10/08/2026
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval Recently updated FDA guidance, Psychedelic Drugs: Considerations for [...]
HRC Technology Solutions LLC Achieves SOC 1 Type 2 and SOC 2 Type 2 Compliance, Reinforcing Secure, AI-Driven Revenue Cycle Management
10/08/2026
SOUTHLAKE, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- HRC Technology Solutions LLC today announced it has achieved SOC 1 Type 2 and SOC 2 Type 2 compliance, independently assessed by ControlCase as its Qualified Security [...]
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
10/08/2026
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a [...]
Mesa Labs Announces First Quarter Results
10/08/2026
LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
10/08/2026
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep [...]
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
InspireMD to Announce Second Quarter 2026 Financial Results
10/08/2026
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its [...]
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
10/08/2026
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval [...]
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08/2026
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, [...]

Pages